The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic
Adult Vaccine Market is projected to reach US$ 22 Billion by the year 2024. Vaccination can help prevent certain diseases in all the people. Nearly all countries across the globe have introduced a well-organized National immunization Programs in their vaccination schedule to overcome the outbreak of vaccine-preventable diseases. Several organizations such as Global Immunization Vision and Strategy (GIVS), WHO’s Global Vaccine Action Plan, The GAVI Alliance are putting their best to reduce the occurrence of vaccine-preventable diseases around the world which certainly is driving the adult vaccine market sturdily.
Rising prevalence of diseases, growing awareness among the people regarding vaccine-preventable diseases, increasing investments by companies to develop new vaccines and increasing governments and other healthcare authorities (Bill & Melinda Gates Foundation) funding for promoting immunization programs as well as for the developments & distribution of the vaccines are some other key factors which are anticipated to augment the growth of global adult vaccine during the forecast period.
Renub Research report titled “Adult Vaccine Market, Global Analysis By Disease [Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Varicella and Travel & Miscellaneous Vaccine], Companies (GlaxoSmithKline, Merck, Sanofi, Pfizer, & Others)” provides a complete analysis of Global Adults Vaccine Market.
By Disease - Pneumococcal Vaccine is likely to grow at noteworthy rate over the coming years
The report studies the market of the following vaccine: Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Varicella, and Travel & Miscellaneous Vaccine. Pneumococcal and Hepatitis together hold the significant market share in global adult vaccine market and is expected to continue so in the forecast period.
By End User – Global Adults Vaccine Market
The report studies the market by end user as Adults. Around the world, thousands of adults become seriously ill, get hospitalized and even die because of diseases that vaccines can help prevent. By getting vaccinated, one can help protect themselves from much of this needless suffering.
Almost 350 Million Adults get vaccinated by 2024
Due to the increasing prevalence of diseases and growing awareness regarding the vaccine-preventable diseases, it is estimated that by the year 2024, nearly 350 million adults get vaccinated; in order to protect themselves from diseases. Some of the vaccines which hold considerable share in terms of adult vaccination include Influenza, Hepatitis, HPV and Pneumonia vaccine.
Regional - Immunization Profile
The report also studies the Immunization profile around the world; By Disease - Measles, Mumps, Rubella, Japanese encephalitis, Tetanus, Pertussis, Yellow Fever. While By Regions, it studies Americas (AMR), Europe (EUR), Africa (AFR), Eastern Mediterranean (EMR), South-East Asia (SEAR), Western Pacific (WPR) and Global.
GlaxoSmithKline, Merck, Sanofi, and Pfizer are some of the top companies that deal efficiently in vaccine business globally. These companies have been studied thoroughly in the report.
Global Adults Vaccine Market has been extensively studied from 3 major points:
1. Adult Vaccines (Disease wise) Market & Forecast
2. Number of Vaccinated Adults (Disease wise) & Forecast
3. Doses of Vaccines Administered in Adults(Disease wise) & Forecast
- Cervical Cancer
- Zoster (Shingles)
- MMR (Measles, Mumps, and Rubella)
- Tap (Diphtheria, Tetanus, Pertussis)
- Travel & Miscellaneous Vaccine
Key Companies Covered in the Report